Assessing Strategies to Mitigate the Effect of Age When Using Fibrosis-4 Index to Screen for Metabolic Dysfunction–Associated Steatotic Liver Disease–Related Liver Fibrosis
Clinical Gastroenterology and Hepatology · 2026-09
DOI: 10.1016/j.cgh.2026.09.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-09. Verfasst von Jeevan Nammi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND & AIMS: Fibrosis-4 (FIB-4) is recommended to screen for liver fibrosis in at-risk individuals, but its performance is limited at extremes of age. This study compared different strategies to limit the effect of age on FIB-4. METHODS: Using 2 independent metabolic dysfunction-associated steatotic liver disease cohorts, we assessed FIB-4 and 4 alternative strategies to detect ≥ F2, ≥F3, and cirrhosis. The strategies assessed were: (1) standard FIB-4 with 1.3 as cutoff; (2) FIB-4, but using a cutoff of 2.0 for ≥65 years; (3) FIB-3 where age was removed from the FIB-4 formula; (4) capped FIB-4 (where 35 or 65 years were used as age inputs in individuals 65 years, respectively), and (5) log-transformed FIB-4, where the natural logarithm of age was used. Magnetic resonance elastography was used as reference in cohort #1 (n = 604), and liver biopsy in cohort #2 (n = 334). The National Health and Nutrition Examination Survey, 2017 to 2020, was used to assess the strategies in an unselected cohort. RESULTS: Among 938 participants (age, 54 ± 12 years; 50% female; body mass index, 34.7 ± 6.7 kg/m2; 42% with diabetes), 20% had ≥ F2, 13% ≥F3, and 3% cirrhosis. All strategies had similar areas under the receiver operating characteristic curve (AUROCs) for detection of ≥F2 or ≥ F3 vs magnetic resonance elastography (AUROCs, 0.76-0.78) or liver biopsy (AUROCs, 0.77-0.81). Based on prespecified or calculated cutoff points, strategies differed in sensitivity and specificity, but without major impact on positive predictive value and negative predictive value. FIB-3 demonstrated a balanced sensitivity-specificity trade-off at age extremes (
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
- Division of Internal Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
- Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama.
- Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama.
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida, Gainesville, Florida.
- Division of Gastroenterology and Hepatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Zitieren
APA
Nammi, J., Southall, W., Huynh, K., Smith, E., Al Diffalha, S., Cusi, K., Gray, M., & Bril, F. (2026). Assessing Strategies to Mitigate the Effect of Age When Using Fibrosis-4 Index to Screen for Metabolic Dysfunction–Associated Steatotic Liver Disease–Related Liver Fibrosis. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.09.003
Vancouver
Nammi J, Southall W, Huynh K, Smith E, Al Diffalha S, Cusi K, et al. Assessing Strategies to Mitigate the Effect of Age When Using Fibrosis-4 Index to Screen for Metabolic Dysfunction–Associated Steatotic Liver Disease–Related Liver Fibrosis. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.09.003
BibTeX
@article{Nammi2026,
author = {Nammi, Jeevan and Southall, William and Huynh, Ky and Smith, Elainea and Al Diffalha, Sameer and Cusi, Kenneth and Gray, Meagan and Bril, Fernando},
title = {Assessing Strategies to Mitigate the Effect of Age When Using Fibrosis-4 Index to Screen for Metabolic Dysfunction–Associated Steatotic Liver Disease–Related Liver Fibrosis},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
doi = {10.1016/j.cgh.2026.09.003}
}
EUVIMED